In this 6-week , single-blind , placebo-controlled trial with optional 6-month open-label extension ( NCT00993668 ) , patients were stratified by concomitant methotrexate ( MTX ) use and randomized to receive CZP 400 mg ( loading dose ; according to CZP label ) or placebo at weeks 0 , 2 , and 4 .